These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 18759508

  • 1. Monitoring the safety of pioglitazone : results of a prescription-event monitoring study of 12,772 patients in England.
    Kasliwal R, Wilton LV, Shakir SA.
    Drug Saf; 2008; 31(10):839-50. PubMed ID: 18759508
    [Abstract] [Full Text] [Related]

  • 2. Risk management and outcomes of adverse events to pioglitazone in primary care in the UK: an observational study.
    Fogg C, Kasliwal R, Shakir SA.
    Drug Saf; 2009; 32(3):229-37. PubMed ID: 19338380
    [Abstract] [Full Text] [Related]

  • 3. Safety and drug utilization profile of varenicline as used in general practice in England: interim results from a prescription-event monitoring study.
    Kasliwal R, Wilton LV, Shakir SA.
    Drug Saf; 2009; 32(6):499-507. PubMed ID: 19459717
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
    Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA.
    Drug Saf; 2009; 32(5):409-18. PubMed ID: 19419235
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000.
    Boshier A, Wilton LV, Shakir SA.
    Eur J Clin Pharmacol; 2003 Dec; 59(10):767-73. PubMed ID: 14615857
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety of zafirlukast: results of a postmarketing surveillance study on 7976 patients in England.
    Twaites BR, Wilton LV, Shakir SA.
    Drug Saf; 2007 Dec; 30(5):419-29. PubMed ID: 17472420
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety profile of modafinil across a range of prescribing indications, including off-label use, in a primary care setting in England: results of a modified prescription-event monitoring study.
    Davies M, Wilton L, Shakir S.
    Drug Saf; 2013 Apr; 36(4):237-46. PubMed ID: 23483377
    [Abstract] [Full Text] [Related]

  • 14. Safety profile of orlistat: results of a prescription-event monitoring study.
    Acharya NV, Wilton LV, Shakir SA.
    Int J Obes (Lond); 2006 Nov; 30(11):1645-52. PubMed ID: 16552401
    [Abstract] [Full Text] [Related]

  • 15. The safety of valsartan: results of a postmarketing surveillance study on 12881 patients in England.
    Biswas PN, Wilton LV, Shakir SW.
    J Hum Hypertens; 2002 Nov; 16(11):795-803. PubMed ID: 12444541
    [Abstract] [Full Text] [Related]

  • 16. Safety of nateglinide as used in general practice in England: results of a prescription-event monitoring study.
    Twaites B, Wilton LV, Layton D, Shakir SA.
    Acta Diabetol; 2007 Dec; 44(4):233-9. PubMed ID: 17874223
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Neuropsychiatric events with varenicline: a modified prescription-event monitoring study in general practice in England.
    Buggy Y, Cornelius V, Fogg C, Kasliwal R, Layton D, Shakir SA.
    Drug Saf; 2013 Jul; 36(7):521-31. PubMed ID: 23657823
    [Abstract] [Full Text] [Related]

  • 19. Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.
    Barrera BA, Wilton L, Harris S, Shakir SA.
    Osteoporos Int; 2005 Dec; 16(12):1989-98. PubMed ID: 16133643
    [Abstract] [Full Text] [Related]

  • 20. Drug utilization of Intrinsa (testosterone patch) in England: interim analysis of a prescription-event monitoring study to support risk management.
    Osborne V, Hazell L, Layton D, Shakir SA.
    Drug Saf; 2010 Mar 01; 33(3):213-21. PubMed ID: 20158285
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.